Oncology & Cancer

Validation of an IHC screening tool for ROS1 gene rearrangements

Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, ...

Oncology & Cancer

Immunohistochemistry effectively detects ALK rearrangement

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma ...

Oncology & Cancer

Tumors with ALK rearrangements can harbor more mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

Oncology & Cancer

Quantifying heterogeneity in breast cancer

A variety of mutations may give rise to breast cancer, but scientists generally assume that it starts off with just a few. That's because later-stage breast cancers tend to have more mutations—they are more heterogeneous—than ...

page 1 from 2